USA flag logo/image

An Official Website of the United States Government

Detection of GPCR Function in Cell-free Nanoscale System

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
76274
Program Year/Program:
2005 / SBIR
Agency Tracking Number:
GM072379
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
INTEGRAL MOLECULAR
3711 MARKET ST Suite 900 PHILADELPHIA, PA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2005
Title: Detection of GPCR Function in Cell-free Nanoscale System
Agency: HHS
Contract: 1R43GM072379-01A1
Award Amount: $289,264.00
 

Abstract:

DESCRIPTION (provided by applicant): The G protein-coupled receptor (GPCR) CXCR4 is a determinant of the pathogenesis of HIV-1 infection and breast cancer, but efforts to develop drugs that modify its function have been unsuccessful. Traditional assays that screen GPCR function mostly use live cells or cell membrane fragments, formats that are limited by poor receptor purity, stringent environmental requirements, unacceptable variability, and an inability to be miniaturized, prohibiting their application to more versatile micro- and nano-scale detection technologies. Furthermore, traditional assays for GPCR activation often involve detection of downstream signaling events such as calcium release which are not stimulated by a number of important GPCRs and G proteins. A nanometer-scale, cell-free assay for GPCR activation that can be applied to microfluidic drug-screening devices could have a major impact on the discovery of drugs to difficult GPCR targets, and this proposal is designed to produce such a system. Our approach has three major advantages compared with existing assays: 1) simplicity, 2) the ability to be miniaturized to the nanometer scale, and 3) the ability to detect diverse and difficult GPCRs that conventional systems fail to detect. The product will facilitate high throughput screening of GPCRs, orphan ligand-receptor pairing, and the development of therapeutics that treat AIDS and breast cancer.

Principal Investigator:

Benjamin Doranz
2159666018
bdoranz@integralmolecular.com

Business Contact:

Benjamin Doranz
2159666018
BDORANZ@INTEGRALMOLECULAR.COM
Small Business Information at Submission:

Integral Molecular
Integral Molecular 3701 Market St, Ste 340 Philadelphia, PA 19104

EIN/Tax ID: 233091965
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No